Efficacy of multi-electrode duty-cycled radiofrequency ablation for pulmonary vein disconnection in patients with paroxysmal and persistent atrial fibrillation
ABSTRACT A novel multi-electrode pulmonary vein ablation catheter (PVAC) combining circular mapping and duty-cycled multi-electrode radiofrequency (RF) energy delivery has been developed to map and isolate the pulmonary veins (PVs). The aim of this study was to assess the efficacy of multi-electrode RF ablation using the PVAC device.
A total of 102 consecutive patients, age 57.9 +/- 9.6 years, with paroxysmal or persistent drug refractory atrial fibrillation (AF) were referred for ablation. All patients had documented AF episodes with an AF duration of 9.3 +/- 7.5 years (range 1.5-25). The mean total procedure time was 139.30 +/- 37.72 (median 135, range 115-172). The mean fluoroscopy time required for PVAC ablation was 17 +/- 12 min (median 16, range 12-33) and the total fluoroscopy time was 32.1 +/- 11.3 min (median 29, range 25-39). The mean multi-electrode RF ablation time required to achieve complete PV isolation was 31 +/- 6.7 min (range 16-51). In eight patients with persistent AF, additional ablations were performed to defragment septal and posterior part of the left atrium. In five patients additional RF ablations using conventional catheters were necessary. After multi-electrode duty-cycled RF ablation, 62 of 102 (60.8%) patients were in sustained sinus rhythm without anti-arrhythmic drugs. The mean follow-up duration was 12.2 +/- 3.9 months (range 6-15).
This novel multi-electrode ablation technique can be used for PV isolation and left atrium ablation with a relatively low medium-term success rate after the first ablation of approximately 61%. Larger studies with longer follow-up are required to evaluate the efficacy and whether multi-electrode RF ablation is associated with a different complication rate compared with standard PV isolation.
- SourceAvailable from: sciencedirect.com[Show abstract] [Hide abstract]
ABSTRACT: Catheter ablation is widely used to treat symptomatic atrial fibrillation (AF) refractory to drug therapy; and can be facilitated by a number of different techniques. To evaluate our performance as a new centre for AF ablation and to evaluate the efficacy of different AF ablation techniques. We employed three techniques in AF ablations; the three-dimensional (3D) mapping approaches (CARTO or Ensite NavX) or multielectrode catheter duty-cycled radiofrequency ablation (pulmonary vein ablation catheter [PVAC]). The immediate restoration of sinus rhythm was considered as acute success; while success at 6 months was determined by the maintenance of sinus rhythm on Holter monitoring. Between March 2008 and March 2010, 109 patients underwent AF ablations (mean age: 58 years; 72% male). Six-month success rates did not differ significantly between CARTO and NavX (40% vs 38%; P=0.81), but the PVAC group achieved greater success than the two 3D-mapping groups combined (68% vs 39%; P=0.004). Paroxysmal AF patients demonstrated greater 6-month success than persistent AF patients (P=0.005); and although the ratio of paroxysmal to persistent AF patients was slightly higher among the PVAC group, logistic regression confirmed PVAC and paroxysmal AF as predictors of success. Single-procedure success at 6 months was 48%. Including redo-ablations, some performed beyond the study period, our overall success rate at 6 months was 65%. Four patients experienced complications, but there were no deaths. Despite being a new centre with relative inexperience, we achieved success rates comparable to those of established tertiary centres. PVAC performed significantly better than the two 3D-mapping approaches.Archives of cardiovascular diseases 06/2011; 104(6-7):396-402. DOI:10.1016/j.acvd.2011.05.003 · 1.66 Impact Factor
- Europace 02/2010; 12(4):455-7. DOI:10.1093/europace/eup415 · 3.05 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Evidence indicates that the combination of left atrial ganglionated plexi (GP) ablation and pulmonary vein (PV) isolation is beneficial for treatment of paroxysmal atrial fibrillation (AF). The purpose of this study was to compare GP and PV ablation with PV isolation alone for treatment of paroxysmal AF. Sixty-seven patients with paroxysmal AF were randomized to either PV isolation using a circular catheter suitable for both mapping and ablation (PV group) or anatomic GP modification followed by PV isolation (GP+PV group). Patients were seen at monthly visits, and 48-hour ambulatory ECG recordings were obtained every 3 months for a predefined follow-up period of 12 months. Primary endpoint was freedom from AF or other sustained atrial arrhythmia recurrence 3 to 12 months postablation after one or two procedures, without antiarrhythmic medications. Recurrence of arrhythmia was documented in 18 (54.5%) patients in the PV group 4.7 ± 1.0 months after ablation, and repeat PV isolation was performed in 7 (21.2%) of these patients 5.1 ± 1.1 months after the first procedure. Recurrence of arrhythmia was documented in 9 (26.5%) patients in the GP+PV group 5.0 ± 1.3 months after ablation, and repeat ablation was performed in 6 (17.6%) of these patients 4.3 ± 0.5 months after the first procedure. At the end of follow-up, 20 (60.6%) patients in the PV group and 29 (85.3%) patients in the GP+PV group remained arrhythmia-free (log rank test, P = .019). Addition of anatomic GP modification to PV isolation confers significantly better outcomes than PV isolation alone during a follow-up period of 12 months.Heart rhythm: the official journal of the Heart Rhythm Society 12/2010; 8(5):672-8. DOI:10.1016/j.hrthm.2010.12.047 · 4.92 Impact Factor